1. X
  2. Pfizer Inc.
Log inSign up
Pfizer Inc.
11.4K posts
Image
user avatar
Pfizer Inc.
@pfizer
We’re celebrating over 175 years of daring scientific innovation and we’re not done yet. Protect your health at PfizerForAll.com on.pfizer.com/CGs
New York, NY
pfizer.com
Joined July 2009
2,101
Following
469.7K
Followers
RepliesRepliesMediaMedia
  • user avatar
    Pfizer Inc.
    @pfizer
    Jul 31
    Not all migraine attacks are random. Hormonal shifts across the menstrual cycle can trigger longer, more severe attacks. Here’s what the research reveals about menstrual migraine: on.pfizer.com/4pP1u0x #MigraineAwareness #HormoneHealth #WomensHealth
    Image
  • user avatar
    Pfizer Inc.
    @pfizer
    Jul 22
    “My daughter is my driving force. She’s what I’m truly living for.” After a rare cancer diagnosis, Isis Kanevsky shares the lessons that ground her as she navigates treatment and survivorship. on.pfizer.com/4wSJVip #CancerSurvivorship #CancerAwareness #RareDisease
    Image
    00:00
  • user avatar
    Pfizer Inc.
    @pfizer
    Jun 30
    GLP-1. GIP. Amylin. NuSH. What sounds like “alphabet soup” is actually reshaping how researchers understand obesity. New science is revealing how hormones, brain signaling, metabolism, and the gut-brain axis influence weight regulation — and is driving updated approaches to
    Image
  • user avatar
    Pfizer Inc.
    @pfizer
    Jun 26
    For years, Dan Morgan has helped doctors understand the role certain medications can play in cancer care. At age 46, he became a patient. Because he was proactive about prostate cancer screening, doctors caught it early. Now, Dan’s sharing his story. on.pfizer.com/4evVVQH
    Image
  • user avatar
    Pfizer Inc.
    @pfizer
    Jun 25
    The first participants have been dosed in VESPER-6 and SOLIS-1, part of 20+ study starts planned across Pfizer's obesity pipeline in 2026. Learn more about our pipeline: pfizer.com/pipeline
    user avatar
    Albert Bourla
    @AlbertBourla
    Jun 25
    We dosed the first participants in VESPER-6, the latest Phase 3 trial of our lead investigational medicine in obesity and started a Phase 2b study testing it in combination with an investigational amylin analog.
    Image

Log in or sign up for X

See what’s happening and join the conversation

Continue with phone
or
Log in with username or email
Terms·Privacy·Cookies·Accessibility·Ads Info·© 2026 X Corp.
Advertisement
Advertisement